Darbepoetin Alfa With or Without Intravenous (IV) Iron
Status:
Completed
Trial end date:
2008-03-01
Target enrollment:
Participant gender:
Summary
To deterime the efficacy of 500 μg and 300 μg darbepoetin alfa administered subcutaneously
(SC) on an every 3 weeks (Q3W) schedule, and the effect of intravenous (IV) iron
supplementation in the treatment of anemia in patients with non-myeloid malignancies who were
receiving multicycle chemotherapy.
Phase:
Phase 2
Details
Lead Sponsor:
Amgen
Treatments:
Darbepoetin alfa Dextrans Iron Iron-Dextran Complex